Consequences of single vs. combination tyrosine kinase inhibitor treatments on ovarian cancer viability. A) Cell viability, in ovarian cancer cell line OVCA429, was evaluated by the CellTiter-Glo luminescence assay after 72 h treatment with EGFR (1 μM gefitinib), MET (1 μM PHA665752), or AXL (AXL shRNA1 and AXL shRNA2) inhibitor alone and together, and HSP90 inhibitors (1 μM 17-AAG). The data were normalized to the DMSO control, and represent the mean values (± s.d.) of quadruplicate cultures (*p < 0.05, **P < 0.01, n = 3). B) Imunoblotting evaluations of AXL expression in OVCA429 cells post-infection AXL shRNA at 72 h.